AMRI: Summary for Albany Molecular Research, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 2:43am EST - Canadian Markets open in 6 hours and 47 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Albany Molecular Research Inc. (AMRI)

On Nov 24: 8.52 USD

0.17 (2.04%)

MORE ON AMRI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Albany Molecular Research, Inc. (NasdaqNM:AMRI) Delayed quote data

After Hours: 8.52

0.00 (0.02%) as of 4:15pm EST on 11/24/09

Last Trade:	8.52 USD
Trade Time:	Nov 24
Change:	0.17 (2.04%)
Prev Close:	8.35
Open:	8.30
Bid:	8.30 x 200
Ask:	9.41 x 100
1y Target Est:	15.00

Day's Range:	8.26 - 8.52
52wk Range:	7.31 - 12.56
Volume:	115,823
Avg Vol (3m):	101,186
Market Cap:	269.60M
P/E (ttm):	30.65
EPS (ttm):	0.28
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add AMRI to Portfolio

Download Data

HEADLINES

•	ALBANY MOLECULAR RESEARCH INC Financials
	EDGAR Online Financials (Fri, Nov 13)

•	AMRIâs quarterly earnings, revenue down
	at bizjournals.com (Mon, Nov 9)

•	ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
	EDGAR Online (Mon, Nov 9)

•	AMRI Announces Third Quarter 2009 Results
	Business Wire (Mon, Nov 9)

•	Q3 2009 Albany Molecular Research Earnings Release - Before Market Open
	CCBN (Mon, Nov 9)

•	AMRI receives $750K milestone payment
	at bizjournals.com (Mon, Nov 2)

•	Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
	Business Wire (Mon, Nov 2)

•	AMRI to Present at the Oppenheimer 20th Annual Healthcare Conference
	Business Wire (Fri, Oct 30)

•	AMRI to Announce Third Quarter Results
	Business Wire (Mon, Oct 26)

•	Daines: Treat flu-like symptoms as H1N1
	at bizjournals.com (Thu, Oct 22)

More Headlines for AMRI...

ANALYST

EPS Est (next year) (Dec-07) :	0.32
EPS Est (in 2 years) (Dec-08) :	0.41
Avg Rec (current)*:	2.5
PEG Ratio:	1.68

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Albany Molecular Research, Inc., a drug discovery and development company, focuses on the identification and development of biologically active small molecules with applications in the drug market.

Full Company Profile

Add to Portfolio

Email to a Friend

•